Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Enrolling By Invitation NCT07703735

Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma

Conditions: Liver Transplantation, Hepatocellular Carcinoma (HCC)

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 371

Sponsor: Seoung Hoon Kim

Summary

This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.

Eligibility Criteria

Inclusion Criteria:• Adult patients (≥18 years) * Underwent living donor liver transplantation for HCC * Transplantation between Jan 2012 - Dec 2023 Exclusion Criteria: * • Deceased donor liver transplantation * Re-transplantation

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07703735). StuddyBuddy aggregates publicly available trial information.